posted on 2025-10-07, 00:25authored byJerry D Monroe, Daniel Fraher, Xiaoqian Huang, Natalie A Mellett, Peter J Meikle, Andrew SinclairAndrew Sinclair, Seth T Lirette, Nita J Maihle, Zhiyuan Gong, Yann Gibert
Abstract
Background
Hepatocellular carcinoma (HCC) is the predominant form of liver cancer and is accompanied by complex dysregulation of lipids. Increasing evidence suggests that particular lipid species are associated with HCC progression. Here, we aimed to identify lipid biomarkers of HCC associated with the induction of two oncogenes, xmrk, a zebrafish homolog of the human epidermal growth factor receptor (EGFR), and Myc, a regulator of EGFR expression during HCC.
Methods
We induced HCC in transgenic xmrk, Myc, and xmrk/Myc zebrafish models. Liver specimens were histologically analyzed to characterize the HCC stage, Oil-Red-O stained to detect lipids, and liquid chromatography/mass spectrometry analyzed to assign and quantify lipid species. Quantitative real-time polymerase chain reaction was used to measure lipid metabolic gene expression in liver samples. Lipid species data was analyzed using univariate and multivariate logistic modeling to correlate lipid class levels with HCC progression.
Results
We found that induction of xmrk, Myc and xmrk/Myc caused different stages of HCC. Lipid deposition and class levels generally increased during tumor progression, but triglyceride levels decreased. Myc appears to control early HCC stage lipid species levels in double transgenics, whereas xmrk may take over this role in later stages. Lipid metabolic gene expression can be regulated by either xmrk, Myc, or both oncogenes. Our computational models showed that variations in total levels of several lipid classes are associated with HCC progression.
Conclusions
These data indicate that xmrk and Myc can temporally regulate lipid species that may serve as effective biomarkers of HCC progression.
Funding
YG is supported by a National Institute of Health grant (P20 GM104357), by a COBRE/MS CEPR National Institute of Health grant (P20GM121334) and by a National Institute of Health grant (R01DE029803) and is supported by the Cancer Center and Research Institute. SL is partially supported by the Mississippi Center for Clinical and Translational Research and the Mississippi Center of Excellence in Perinatal Research COBRE funded by the National Institute of General Medical Sciences of the National Institutes of Health under Award Numbers 5U54GM115428 and P20GM121334. ZG is supported by grants from the Ministry of Education, Singapore (R154000B70114 and R154000B88112).
Funder: National Institute of Health | Grant ID: R01DE029803
Funder: National Institute of Health | Grant ID: P20 GM104357
Funder: COBRE/MS CEPR National Institute of Health | Grant ID: P20GM121334
Funder: Cancer Center and Research Institute
Funder: Mississippi Center for Clinical and Translational Research
Funder: Mississippi Center of Excellence in Perinatal Research COBRE - National Institute of General Medical Sciences of the National Institutes of Health | Grant ID: P20GM121334
Funder: Mississippi Center of Excellence in Perinatal Research COBRE - National Institute of General Medical Sciences of the National Institutes of Health | Grant ID: 5U54GM115428
Funder: Ministry of Education, Singapore | Grant ID: R154000B70114
Funder: Ministry of Education, Singapore | Grant ID: R154000B88112
Funder: National Institute of General Medical Sciences | Grant ID: P20GM121334
Funder: National Institute of General Medical Sciences | Grant ID: P20GM104357